Cargando…
SP2-3 The impact of the COVID-19 global pandemic on oncology drug development, clinical research and R&D in Japan
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311552/ http://dx.doi.org/10.1016/j.annonc.2021.05.361 |
| _version_ | 1783728981168619520 |
|---|---|
| author | Shimizu, Toshio |
| author_facet | Shimizu, Toshio |
| author_sort | Shimizu, Toshio |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8311552 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | European Society for Medical Oncology. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-83115522021-07-26 SP2-3 The impact of the COVID-19 global pandemic on oncology drug development, clinical research and R&D in Japan Shimizu, Toshio Ann Oncol Article European Society for Medical Oncology. Published by Elsevier Ltd. 2021-07 2021-07-26 /pmc/articles/PMC8311552/ http://dx.doi.org/10.1016/j.annonc.2021.05.361 Text en Copyright © 2021 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Shimizu, Toshio SP2-3 The impact of the COVID-19 global pandemic on oncology drug development, clinical research and R&D in Japan |
| title | SP2-3 The impact of the COVID-19 global pandemic on oncology drug development, clinical research and R&D in Japan |
| title_full | SP2-3 The impact of the COVID-19 global pandemic on oncology drug development, clinical research and R&D in Japan |
| title_fullStr | SP2-3 The impact of the COVID-19 global pandemic on oncology drug development, clinical research and R&D in Japan |
| title_full_unstemmed | SP2-3 The impact of the COVID-19 global pandemic on oncology drug development, clinical research and R&D in Japan |
| title_short | SP2-3 The impact of the COVID-19 global pandemic on oncology drug development, clinical research and R&D in Japan |
| title_sort | sp2-3 the impact of the covid-19 global pandemic on oncology drug development, clinical research and r&d in japan |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311552/ http://dx.doi.org/10.1016/j.annonc.2021.05.361 |
| work_keys_str_mv | AT shimizutoshio sp23theimpactofthecovid19globalpandemicononcologydrugdevelopmentclinicalresearchandrdinjapan |